Cara Therapeutics: Performance and Estimates for Q3

Cara Therapeutics

Cara Therapeutics (CARA) is a clinical-stage biotechnology company that develops new chemical entities for managing pain and pruritus. It reported EPS of -$0.52 on revenues of $2.87 million in the second quarter.

Cara Therapeutics: Performance and Estimates for Q3

The above chart compares Cara Therapeutics’ revenues since the first quarter of 2018 and shows the estimate for the third quarter.

Quarterly revenue performance

Cara Therapeutics reported revenues of $2.87 million in the second quarter compared to no revenues in the second quarter of 2017. Its license and milestone fees were $2.87 million.

Cara Therapeutics hasn’t generated any revenues from product sales, and it doesn’t expect to report any in the near future. Reported revenues include license and milestone payments, collaborative revenues, and clinical compound revenues. The company has license agreements with Vifor Fresenius Medical Care Renal Pharma, Maruishi Pharmaceutical, and Chong Kun Dang Pharmaceutical. The company hasn’t reported royalty revenues from any of its collaborations.

Estimates for Q3 2018

Wall Street analysts estimate that Cara Therapeutics will report revenues of $3.4 million for the third quarter of 2018.

Performance for the first half of the year

Cara Therapeutics reported revenues of $2.87 million in the first half of 2018. That’s ~200% year-over-year growth compared to $0.91 million in the first half of 2017.

The SPDR S&P Biotech ETF (XBI) holds 0.7% of its total investments in Cara Therapeutics (CARA), 1.4% in Gilead Sciences (GILD), 1.3% in Seattle Genetics (SGEN), and 1.3% in Celgene (CELG).